RNA-targeting small molecules are rapidly emerging as a powerful therapeutic reality. From modulating splicing to directly binding RNAs, these molecules offer a revolutionary approach to treating previously undruggable diseases across neurodegenerative, cancer and rare disorders. In 2025 alone, the field has seen major collaborations, including Wayfinder Biosciences with Daiichi Sankyo, Ono Pharmaceutical with Reborna Biosciences, […]

The 2nd Innovation in Obesity Therapeutics Summit will return to San Diego this December. Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly and Boehringer Ingelheim, who will share their groundbreaking research and strategies. The pressure is on to develop best-in-class treatments that transform patient lives. Don't miss this pivotal opportunity […]

With major FDA changes already reshaping the regulatory landscape - and global agencies ramping up scrutiny - 2025 is a pivotal year for cell and gene therapy regulatory professionals. With CBER leadership changes, new FDA draft guidance on post-approval CMC, and potency assays facing heightened scrutiny, the environment is rapidly evolving. Global efforts to align […]

The World’s Only Industry-Specific Forum on AI-Oriented Skills-Centric Workforce Transformation in Life Sciences Most roles in biopharma organizations will undergo an AI-driven transformation in the coming years. But exactly how that transformation manifests itself, in what jobs, with what skills, and across what proportion of our workforces is not yet fully clear. What is clear, […]

Navigate New FDA Leadership, Harness AI-Powered Submissions & Align Technical Innovation with the Latest Nonclinical, Clinical & CMC Guidance to Overcome Regulatory Challenges and Accelerate Your Path to Clinic & Market With major FDA changes already reshaping the regulatory landscape - and global agencies ramping up scrutiny - 2025 is a pivotal year for cell […]

The 6th Gene Therapy for Ophthalmic Disorders Summit returns to Raleigh, North Carolina, as the leading industry forum dedicated to accelerating the development of gene therapies for both rare and common eye diseases. With irreversible vision loss progressing rapidly in many conditions, gene therapy continues to emerge as a critical one-time intervention that can preserve and restore […]

Ever since the field-defining studies in Nature Medicine and the New England Journal demonstrated that cell therapies could hold lasting potential in lupus and beyond, the field has grown from strength to strength. With a surge of billion-dollar investments, the release of new groundbreaking data, and recent real-world clinical progression, the autoimmune cell therapy field is […]

With the European oncology market increasingly focused on emerging modalities, highlighted by AbbVie’s recent licensing agreement with Ichnos Glenmark Innovation for their trispecific antibody, Boehringer Ingelheim’s partnership with Tempus to advance their cancer pipeline and the FDA’s new roadmap and the EMA encouraging drug developers to use non-animal tests in submissions, there has never been a more important year to stay up to […]

As biopharma organizations decrease their budgets and move away from a recruitment-centric approach, the need to develop existing talent to fill key technical skills gaps has never been more mission critical. This December in Boston, LEAP TD: Life Sciences will bring together senior talent development leaders from across biopharma to explore how learning and development can directly support […]

With the launch of the FDA’s Project Optimus, and the evolving clinical pharmacology guidelines for ADCs, the need to identify an optimal clinical dose that balances safety with efficacy has never been more evident. Bringing together a focused audience of clinical pharmacology, PK, pharmacometrics, modelling, and bioanalysis specialists, the 2nd ADC Pharmacokinetics & Clinical Pharmacology […]

Unlocking Safer, More Efficient Delivery to Targeted Brain Regions by Advancing Direct, & Systemic Delivery to the CNS Via TfR1 & Beyond Despite milestones such as Roche’s Trontinemab Brainshuttle™ achieving robust amyloid clearance, challenges remain in reaching targeted brain regions, improving predictive modelling, ensuring efficacy and penetrance, and developing safer, targeted delivery approaches. Join 100+ […]

The race to deliver safe, effective non-opioid pain therapeutics has never been more urgent - or more achievable. After decades of setbacks, the field is achieving long-awaited progress with recent regulatory approvals from Tonix and Vertex, strategic acquisitions from Eli Lilly, and late-stage successes validating the commercial potential of novel mechanisms. However, the clinical pathway […]

With global cases of AMD, DME, and glaucoma rapidly increasing, ophthalmic drug R&D is accelerating to meet urgent unmet needs. However, poor treatment adherence, invasive procedures, and adverse side effects continue to limit therapeutic success, highlighting the critical need for optimized delivery approaches. Recent developments, including Genentech’s Susvimo label expansion, advances in sustained-release and suprachoroidal delivery […]

2025 is proving to be a landmark year for RNAi. From Alnylam’s first approval in hemophilia to Novartis’ $1.2 billion acquisition of Avidity Biosciences and GSK diving into COPD with an $85 million siRNA licensing deal, the headlines haven’t stopped. RNAi is officially outgrowing its liver roots and entering a new era of therapeutic expansion. […]

Molecular glues are leading the charge in the race to drug the previously undruggable, and 2025 has seen continued investment and partnerships driving innovation in this field. Returning as the industry’s only dedicated meeting, the 4th Molecular Glue Drug Development Summit brings top experts from biopharma and academia together for intimate networking and scientific content sharing. Designed to address the unique challenges of molecular glues, this meeting […]

The 5th mRNA-Based Therapeutics Summit Europe is the leading European industry-focused forum dedicated to accelerating the safe, scalable, and clinically impactful development of messenger RNA (mRNA) medicines. Returning for its fifth year in Berlin from 27 - 29 January 2026, this essential meeting unites 170+ senior leaders across R&D, CMC (Chemistry, Manufacturing, and Controls), Regulatory […]

The 6th Age-Related Disease Therapeutics Summit is the leading global meeting dedicated to advancing therapies that target the biology of aging and age-related diseases. Over three days, the summit brings together senior decision-makers from biopharma, biotech innovators, investors, and academic researchers to accelerate the development and commercialization of next-generation therapeutics. As the aging population grows, […]

Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity in tumor modeling. As the FDA phases out animal testing requirements and NIH redirects funding away from animal-only studies, the oncology landscape is transforming. Exciting modalities like ADCs, bispecifics, T-cell engagers demand smarter, more predictive […]

Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as α-synuclein, neuroinflammation, and metabolic targets. Against the backdrop of a globally surging patient population, the urgency for more effective, disease-modifying interventions has never been greater. In its 14th year, the Alzheimer’s and Parkinson’s Drug Development Summit is committed to spotlighting […]

The past decade has transformed liquid biopsy, which was previously just an exciting concept, into a routine, commercially viable technology that is saving patients’ lives and transforming clinical trials. Uniting the field in San Diego February 3-5, 2026 for 3 days of data- and strategy-driven presentations and networking sessions, the 10th Liquid Biopsy for Precision […]

With Novartis committing $750M to ProFound Therapeutics to discover new cardiovascular candidates, and Illumina acquiring SomaLogic for $425 to expand its proteomic capabilities just this year alone, the increasing recognition of proteomics as a transformative force in drug discovery is unquestionable. Returning to Boston for its second year, the Proteomics-Based Drug Discovery Summit is the premier industry event […]

The Longest Standing & Pre-Eminent European ADC Forum 16th World ADC London | 800+ Industry Attendees | 240+ Companies | 110+ Global Speakers With traditional ADCs now fulfilling their potential to reshape oncology care, the bioconjugate community is doubling down on differentiation to ensure the next generation delivers meaningful patient impact. Returning as the longest-standing […]

Across pharma, biotech, chemicals, FMCG, and beyond, laboratory leaders are facing the same challenge: how to turn the vision of a smart, digital lab into reality. From harmonising data and making it AI-ready to unlocking the true value of automation, the journey from concept to execution is complex - but critical. SmartLab Exchange Europe 2026 […]

The Measuring Impact in Medical Affairs Summit is uniting Medical Affairs leaders from across pharma and biotech to define, benchmark, and standardize meaningful KPIs that capture the true value of Medical Affairs activities. As Medical Affairs cements its role as the strategic bridge between R&D and commercialization, the pressure to quantify and communicate impact has never been […]

As regulators and payers increasingly elevate the importance of RWE in submission and reimbursement requirements, the upcoming EHDS regulation marks a landmark move towards data sharing, and increasingly robust AI transforms big data analysis, it has never been more critical to harness RWE to uncover unmet needs, demonstrate treatment value beyond the clinical trial setting, […]

Now in its 8th year, LEAP HR: Life Sciences Europe is where the industry’s most ambitious HR leaders come together to find new solutions to their most pressing people challenges that they can immediately deploy to demonstrate meaningful business impact. Uncover the boldest strategies for driving talent agility, embedding AI and analytics, and building future-ready workforces - […]

Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster, & Biotech Access to International Partnerships & Capital With fast, cost-effective clinical infrastructure, generous government incentives, and simplified regulatory pathways, Asia’s biotech ecosystem has emerged as a global launchpad for innovation. Western pharma and biotech companies are increasingly turning to de-risked […]

The 7th Annual AI in Drug Discovery Conference, hosted by SAE Media Group, takes place 9-10 March 2026 at Hilton London Kensington. This event explores how AI, machine learning, and automation are transforming drug discovery – from generative design and molecular modelling to clinical trial optimisation. Attendees will hear from Big Pharma and Biotech senior […]

Novel conjugates have become one of the most competitive and rapidly evolving areas in the precision oncology landscape. Companies are looking beyond traditional ADCs towards novel mechanism of action payloads and differentiated targeting formats for overcoming drug resistance, improved therapeutic windows and to make an impact in cancers which don’t respond to traditional ADCs, as […]

The 11th Innate Killer Summit stands at the forefront of innovation in innate immunity, offering an unparalleled platform for exploring the next generation of NK cell-based therapies and innate immune strategies. As the biopharma industry accelerates its focus on immuno-oncology and cell therapy, this is the only summit that brings together leading experts and decision-makers […]